Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &…
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage…
CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company,…
Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an…
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double…
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific…
Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and…
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma…
BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices…